The present invention relates to combinations of anti-C5 antibodies and antigen-binding fragments which have been determined to exhibit superior activity relative to that of a single anti-C5 antibody or fragment. The combinations include anti-C5 antibodies and antigen-binding fragments which do not compete with one another from C5 binding. Bispecific antibodies comprising antigen-binding domains which do not compete and/or bind the same epitope on C5 are also provided. Compositions and therapeutic methods relating to such anti-C5 combinations and bispecific antibodies are provided herein.

The present invention relates to combinations of anti-C5 antibodies and antigen-binding fragments which have been determined to exhibit superior activity relative to that of a single anti-C5 antibody or fragment. The combinations include anti-C5 antibodies and antigen-binding fragments which do not compete with one another from C5 binding. Bispecific antibodies comprising antigen-binding domains which do not compete and/or bind the same epitope on C5 are also provided. Compositions and therapeutic methods relating to such anti-C5 combinations and bispecific antibodies are provided herein.

The present invention relates to the identification of key residues within mouse lgG3 antibodies (mAbs) that are responsible for intermolecular cooperativity and their transfer into lgG1 antibodies in order to enhance their functional affinity and direct cell killing.

Disclosed herein are humanized antibodies, antigen-binding fragments thereof, and antibody conjugates, that are capable of specifically binding to certain biantennary Lewis antigens, which antigens are expressed in a variety of cancers. The presently disclosed antibodies are useful to target antigen-expressing cells for treatment or detection of disease, including various cancers. Also provided are polynucleotides, vectors, and host cells for producing the disclosed antibodies and antigen-binding fragments thereof. Pharmaceutical compositions, methods of treatment and detection, and uses of the antibodies, antigen-binding fragments, antibody conjugates, and compositions are also provided.

Methods of preparing influenza viruses having altered immunodominant epitopes in HA, e.g., having one or more residues in one or more of antigenic sites A-E in HA altered, and viral vectors, e.g., influenza virus VLPs or non-influenza viruses or VLPs thereof expressing or having influenza HAs with altered immunogenicity as a result of altered immunodominant epitopes therein are provided.

Methods of preparing influenza viruses having altered immunodominant epitopes in HA, e.g., having one or more residues in one or more of antigenic sites A-E in HA altered, and viral vectors, e.g., influenza virus VLPs or non-influenza viruses or VLPs thereof expressing or having influenza HAs with altered immunogenicity as a result of altered immunodominant epitopes therein are provided.

A method comprising: providing aqueous antibodies; cationizing the aqueous antibodies by the addition of stoichiometric amounts of an excess of a positively-charged crosslinker in the presence of a coupling reagent; titrating the cationized antibodies with a counter anionic polymer until the antibody cation/anion pair solution becomes negative by zeta potential measurement, to create at least one antibody cation/anion pair in aqueous solution. The antibodies are one of anti-hemoglobin antibodies, anti-horse spleen ferritin IgG antibodies, or blood-typing IgM Anti-A antibodies, single-chain antibodies from camelids, monoclonal Anti-Flag antibodies, monoclonal Anti-HRP2 to Plasmodium falciparum, polyclonal Anti-neuropeptide Y, and polyclonal Anti-human troponin. The antibody cation/anion pair solution may be lyophilized to remove all of the water, forming a lyophilized solid, and the lyophilized solid may be heated to generate an antibody ionic liquid.

A method comprising: providing aqueous antibodies; cationizing the aqueous antibodies by the addition of stoichiometric amounts of an excess of a positively-charged crosslinker in the presence of a coupling reagent; titrating the cationized antibodies with a counter anionic polymer until the antibody cation/anion pair solution becomes negative by zeta potential measurement, to create at least one antibody cation/anion pair in aqueous solution. The antibodies are one of anti-hemoglobin antibodies, anti-horse spleen ferritin IgG antibodies, or blood-typing IgM Anti-A antibodies, single-chain antibodies from camelids, monoclonal Anti-Flag antibodies, monoclonal Anti-HRP2 to Plasmodium falciparum, polyclonal Anti-neuropeptide Y, and polyclonal Anti-human troponin. The antibody cation/anion pair solution may be lyophilized to remove all of the water, forming a lyophilized solid, and the lyophilized solid may be heated to generate an antibody ionic liquid.

A method for creating an antibody ionic liquid, comprising: providing aqueous anti-A, anti-B, or anti-Rh antibodies; cationizing the aqueous antibodies by the addition of stoichiometric amounts of an excess of a positively-charged crosslinker in the presence of a coupling reagent; titrating the cationized antibodies with a counter anionic polymer to create at least one antibody cation/anion pair in aqueous solution until the antibody cation/anion pair solution becomes negative by zeta potential measurement. The method may further comprise lyophilizing the antibody cation/anion pair solution to remove all of the water, forming a lyophilized solid; and heating the lyophilized solid to generate a protein ionic liquid. Cationized antibodies may be purified of excess coupling reagents by dialysis in water by a membrane, and the antibody cation/anion solution may be dialyzed to remove excess anionic polymer with a similar membrane.

A method for creating an antibody ionic liquid, comprising: providing aqueous anti-A, anti-B, or anti-Rh antibodies; cationizing the aqueous antibodies by the addition of stoichiometric amounts of an excess of a positively-charged crosslinker in the presence of a coupling reagent; titrating the cationized antibodies with a counter anionic polymer to create at least one antibody cation/anion pair in aqueous solution until the antibody cation/anion pair solution becomes negative by zeta potential measurement. The method may further comprise lyophilizing the antibody cation/anion pair solution to remove all of the water, forming a lyophilized solid; and heating the lyophilized solid to generate a protein ionic liquid. Cationized antibodies may be purified of excess coupling reagents by dialysis in water by a membrane, and the antibody cation/anion solution may be dialyzed to remove excess anionic polymer with a similar membrane.